Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks 2d
Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying Barchart 3d
Intellia Announces Rolling BLA Submission for Lonvo-Z, CRISPR Therapy for HAE Rare Disease Advisor 4d
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing Simply Wall St 03:00 Wed, 29 Apr
Could 'fusion proteins' reduce errors in a promising gene-editing tool? LabOnline 1d Biology Cancer Genetics All sources
CRISPR Therapeutics AG (CRSP) is a trending stock: Facts to know before betting on it Zacks 13h CRISPR Therapeutics Biology All sources
Clinical Trial begins for PBGENE-DMD, Duchenne muscular dystrophy gene editing therapy Rare Disease Advisor 4d Biology Global Health Genetics
Intellia Therapeutics stock is down nearly 95% from its record highs but cathie wood keeps buying Barchart 3d Cathie Wood Biology Biotechnology All sources
Gene Therapy designed by Harvard researchers restores hearing in Clinical Trial The Harvard Crimson 1d Nature
New discovery challenges a decades-old assumption in HIV biology News-Medical.Net 2d HIV Universities T-Cells
Inspiring the next generation: Highlights from the neuroscience event Columbia University Department of Surgery 3d Neuroscience Alzheimer's Health
Structure and druggable conformation of the homodimeric lipoprotein transporter of Acinetobacter baumannii Nature.com 3d Nature Science
